Last reviewed · How we verify
GSK217744
GSK217744 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
GSK217744 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Inflammatory bowel disease (Crohn's disease or ulcerative colitis).
At a glance
| Generic name | GSK217744 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce excessive inflammatory responses in conditions characterized by immune dysregulation. The drug was developed to provide anti-inflammatory effects with potentially improved tolerability compared to earlier PDE4 inhibitors.
Approved indications
- Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Common side effects
- Nausea
- Diarrhea
- Headache
- Vomiting
Key clinical trials
- Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (PHASE2)
- Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |